Do I need body-composition monitoring, hydration guidance, constipation support, or referral to a registered dietitian
Segn las guas de la American Diabetes Association (ADA), los agonistas del receptor GLP-1 con beneficio cardiovascular demostrado se recomiendan para pacientes con diabetes tipo 2 que tienen enfermedad cardiovascular aterosclertica o alto riesgo cardiovascular, independientemente del uso de metformina
CagriSema: Fixed-ratio combination of two separate molecules -- cagrilintide (long- acting amylin analog) and semaglutide (GLP-1 agonist) -- co-administered in a single weekly injection
consider ECG if clinically indicated Nutritional status : Assess current dietary intake, eating patterns, and screen for disordered eating behaviours Mental health evaluation : Screen for depression, anxiety, or other psychiatric comorbidities that may affect treatment adherence or outcomes Weight and metabolic parameters : Record baseline weight, BMI, waist circumference, and relevant blood tests (HbA1c, lipid profile, renal function) Pregnancy status : Exclude pregnancy and discuss contraception requirements (Wegovy is contraindicated in pregnancy) Treatment should begin with a dose of 0.25 mg once weekly, increasing every 4 weeks (0.5 mg, 1.0 mg, 1.7 mg) to reach the maintenance dose of 2.4 mg if tolerated